search
Back to results

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA)

Primary Purpose

Chronic Obstructive Pulmonary Disease (COPD)

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo
Tozorakimab
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring Chronic Obstructive Pulmonary Disease, COPD, tozorakimab, MEDI3506, exacerbations, ICS, LABA/LAMA

Eligibility Criteria

40 Years - 130 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Participant must be ≥ 40 years of age and capable of giving signed informed consent. Documented diagnosis of COPD for at least one year prior to enrolment. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment. Documented optimised inhaled dual or triple therapy for at least 3 months prior to enrolment. Smoking history of ≥ 10 pack-years. CAT total score ≥ 10, with each of the phlegm (sputum) and cough items with a score ≥ 2 Exclusion Criteria: Clinically important pulmonary disease other than COPD. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms. Radiological findings of pulmonary nodules suspicious for lung cancer, as per applicable guidances, without appropriate follow up prior to randomisation. Radiological findings suggestive of acute infection. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18 Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection. Significant COVID-19 illness within the 6 months prior to enrolment. Unstable cardiovascular disorder. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure. History of active severe inflammatory bowel disease or colitis within one year prior to enrolment, or unexplained diarrhoea within the 4 weeks prior to randomisation. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C) Evidence of active liver disease, including jaundice during screening. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms. Participants who have evidence of active TB. History of partial or total lung resection. Scheduled major surgical procedure during the course of the study. Participants that have previously received tozorakimab. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.

Sites / Locations

  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Tozorakimab

Placebo

Arm Description

Dosing subcutaneously tozorakimab

Dosing subcutaneously with equivalent volume to tozorakimab

Outcomes

Primary Outcome Measures

Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]).

Secondary Outcome Measures

Annualized rate of moderate to severe COPD exacerbations in former or current smokers.
The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.
Change from baseline in SGRQ total score from in former smokers
Difference in mean change from baseline in SGRQ total score in former smokers.
Change from baseline in SGRQ total score from in the overall population of current and former smokers.
Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.
Annualized rate of severe COPD exacerbations in former smokers
The rate ratio of severe COPD exacerbations will be assessed in former smokers.
Annualized rate of severe COPD exacerbations in former or current smokers
The rate ratio of severe COPD exacerbations will be assessed in the overall population of current and former smokers.
Change from baseline in E-RS:COPD total score in former smokers
Difference in mean change in E-RS:COPD total score from baseline in former smokers.
Change from baseline in E-RS:COPD total score in former or current smokers
Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former or current smokers
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.
Time to first moderate to severe COPD exacerbation
Time to first moderate to severe COPD exacerbation compared with placebo.
Time to first severe COPD exacerbation
Time to first severe COPD exacerbation compared with placebo.
Change from baseline in CAT total score
Change from baseline in CAT total score compared with placebo.
Proportion of participants achieving MCID in CAT score
Proportion of participants achieving MCID in CAT score (percentage of participants with a decrease in CAT total score of ≥ 2 points from baseline).
Proportion of participants achieving MCID in SGRQ total score
Proportion of participants achieving MCID in SGRQ score (percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline).
Proportion of participants achieving MCID in E-RS:COPD total score
Proportion of participants achieving MCID in E-RS:COPD total score (percentage of participants with a decrease in E-RS:COPD total score of ≥ 2 points from baseline).
Annualized rate of healthcare resource utilization
Annualized rate of healthcare resource utilization.
Change from baseline in rescue medication
Change from baseline (difference in mean number of puffs/day) in rescue medication use.
Trough serum concentrations of tozorakimab
Pharmacokinetics: concentrations of tozorakimab in trough serum.
Presence of anti-drug antibodies
Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.
Time to death
Time to death (all-cause mortality)

Full Information

First Posted
August 25, 2023
Last Updated
October 12, 2023
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT06040086
Brief Title
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Acronym
MIRANDA
Official Title
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (MIRANDA)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 22, 2023 (Actual)
Primary Completion Date
September 10, 2026 (Anticipated)
Study Completion Date
December 7, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease (COPD)
Keywords
Chronic Obstructive Pulmonary Disease, COPD, tozorakimab, MEDI3506, exacerbations, ICS, LABA/LAMA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tozorakimab
Arm Type
Experimental
Arm Description
Dosing subcutaneously tozorakimab
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Dosing subcutaneously with equivalent volume to tozorakimab
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
Intervention Type
Drug
Intervention Name(s)
Tozorakimab
Intervention Description
Administered subcutaneously tozorakimab and placebo throughout the study.
Primary Outcome Measure Information:
Title
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
Description
The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]).
Time Frame
Over 52 weeks
Secondary Outcome Measure Information:
Title
Annualized rate of moderate to severe COPD exacerbations in former or current smokers.
Description
The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.
Time Frame
Over 52 weeks
Title
Change from baseline in SGRQ total score from in former smokers
Description
Difference in mean change from baseline in SGRQ total score in former smokers.
Time Frame
Over 52 weeks
Title
Change from baseline in SGRQ total score from in the overall population of current and former smokers.
Description
Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.
Time Frame
Over 52 weeks
Title
Annualized rate of severe COPD exacerbations in former smokers
Description
The rate ratio of severe COPD exacerbations will be assessed in former smokers.
Time Frame
Variable duration period up to study completion, maximum of approximately 3 years
Title
Annualized rate of severe COPD exacerbations in former or current smokers
Description
The rate ratio of severe COPD exacerbations will be assessed in the overall population of current and former smokers.
Time Frame
Variable duration period up to study completion, maximum of approximately 3 years
Title
Change from baseline in E-RS:COPD total score in former smokers
Description
Difference in mean change in E-RS:COPD total score from baseline in former smokers.
Time Frame
Over 52 weeks
Title
Change from baseline in E-RS:COPD total score in former or current smokers
Description
Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.
Time Frame
Over 52 weeks
Title
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers
Description
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.
Time Frame
Week 52, over 52 weeks
Title
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former or current smokers
Description
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.
Time Frame
Week 52, over 52 weeks
Title
Time to first moderate to severe COPD exacerbation
Description
Time to first moderate to severe COPD exacerbation compared with placebo.
Time Frame
Over 52 weeks
Title
Time to first severe COPD exacerbation
Description
Time to first severe COPD exacerbation compared with placebo.
Time Frame
Variable duration period up to study completion, maximum of approximately 3 years
Title
Change from baseline in CAT total score
Description
Change from baseline in CAT total score compared with placebo.
Time Frame
Week 52
Title
Proportion of participants achieving MCID in CAT score
Description
Proportion of participants achieving MCID in CAT score (percentage of participants with a decrease in CAT total score of ≥ 2 points from baseline).
Time Frame
Week 52
Title
Proportion of participants achieving MCID in SGRQ total score
Description
Proportion of participants achieving MCID in SGRQ score (percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline).
Time Frame
Week 52
Title
Proportion of participants achieving MCID in E-RS:COPD total score
Description
Proportion of participants achieving MCID in E-RS:COPD total score (percentage of participants with a decrease in E-RS:COPD total score of ≥ 2 points from baseline).
Time Frame
Week 52
Title
Annualized rate of healthcare resource utilization
Description
Annualized rate of healthcare resource utilization.
Time Frame
Variable duration period up to study completion, maximum of approximately 3 years
Title
Change from baseline in rescue medication
Description
Change from baseline (difference in mean number of puffs/day) in rescue medication use.
Time Frame
Over 52 weeks
Title
Trough serum concentrations of tozorakimab
Description
Pharmacokinetics: concentrations of tozorakimab in trough serum.
Time Frame
Over 52 weeks
Title
Presence of anti-drug antibodies
Description
Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.
Time Frame
Over 52 weeks
Title
Time to death
Description
Time to death (all-cause mortality)
Time Frame
Variable duration period up to study completion, maximum of approximately 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant must be ≥ 40 years of age and capable of giving signed informed consent. Documented diagnosis of COPD for at least one year prior to enrolment. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment. Documented optimised inhaled dual or triple therapy for at least 3 months prior to enrolment. Smoking history of ≥ 10 pack-years. CAT total score ≥ 10, with each of the phlegm (sputum) and cough items with a score ≥ 2 Exclusion Criteria: Clinically important pulmonary disease other than COPD. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms. Radiological findings of pulmonary nodules suspicious for lung cancer, as per applicable guidances, without appropriate follow up prior to randomisation. Radiological findings suggestive of acute infection. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18 Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection. Significant COVID-19 illness within the 6 months prior to enrolment. Unstable cardiovascular disorder. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure. History of active severe inflammatory bowel disease or colitis within one year prior to enrolment, or unexplained diarrhoea within the 4 weeks prior to randomisation. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C) Evidence of active liver disease, including jaundice during screening. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms. Participants who have evidence of active TB. History of partial or total lung resection. Scheduled major surgical procedure during the course of the study. Participants that have previously received tozorakimab. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
AstraZeneca Clinical Study Information Center
Phone
1-877-240-9479
Email
information.center@astrazeneca.com
Facility Information:
Facility Name
Research Site
City
Decatur
State/Province
Alabama
ZIP/Postal Code
35603
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Sheffield
State/Province
Alabama
ZIP/Postal Code
35660
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33435
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Bowling Green
State/Province
Kentucky
ZIP/Postal Code
42101
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
McKinney
State/Province
Texas
ZIP/Postal Code
75069
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Roy
State/Province
Utah
ZIP/Postal Code
84067
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Caba
ZIP/Postal Code
C1425BEN
Country
Argentina
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Brussels
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Liege
ZIP/Postal Code
4000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Mechelen
ZIP/Postal Code
2800
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Namur
ZIP/Postal Code
5101
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Barretos
ZIP/Postal Code
14784-400
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Campina Grande do Sul
ZIP/Postal Code
83.430-000
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Campinas
ZIP/Postal Code
13060-080
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Campinas
ZIP/Postal Code
13060-904
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90035074
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90610-000
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
91010-006
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Sao Bernardo do Campo
ZIP/Postal Code
09715090
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
05403-000
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Valinhos
ZIP/Postal Code
13271-130
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Burlington
State/Province
Ontario
ZIP/Postal Code
L7N 3V2
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
St Charles Borromee
State/Province
Quebec
ZIP/Postal Code
J6E 2B4
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 0W8
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Brest Cedex
ZIP/Postal Code
29609
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Epagny Metz-Tessy
ZIP/Postal Code
74370
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Libourne Cedex
ZIP/Postal Code
33505
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Lyon Cedex 04
ZIP/Postal Code
69317
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Quimper cedex
ZIP/Postal Code
29000
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Augsburg
ZIP/Postal Code
86150
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10119
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10717
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10787
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10961
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
12157
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
12159
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
12203
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
13187
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Darmstadt
ZIP/Postal Code
64283
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Essen
ZIP/Postal Code
45127
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Frankfurt/Main
ZIP/Postal Code
60389
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Frankfurt
ZIP/Postal Code
60596
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Großhansdorf
ZIP/Postal Code
22927
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Halle (Saale)
ZIP/Postal Code
06120
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Halle
ZIP/Postal Code
06108
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Hannover
ZIP/Postal Code
30159
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Köln
ZIP/Postal Code
51069
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Leipzig
ZIP/Postal Code
04299
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Marburg
ZIP/Postal Code
35037
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Moers
ZIP/Postal Code
47441
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
München-Pasing
ZIP/Postal Code
81241
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
München
ZIP/Postal Code
80335
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Nürnberg
ZIP/Postal Code
90419
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Peine
ZIP/Postal Code
31224
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Solingen
ZIP/Postal Code
42699
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Athens
ZIP/Postal Code
11521
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Exohi Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Heraklion
ZIP/Postal Code
71409
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Ioannina
ZIP/Postal Code
45500
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1194
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Edelény
ZIP/Postal Code
3780
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Encs
ZIP/Postal Code
3860
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Gödöllő
ZIP/Postal Code
2100
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Hajdúnánás
ZIP/Postal Code
4080
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Mosonmagyaróvár
ZIP/Postal Code
9200
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Pécs
ZIP/Postal Code
7635
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Püspökladány
ZIP/Postal Code
4150
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Szolnok
ZIP/Postal Code
5000
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Százhalombatta
ZIP/Postal Code
2440
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Székesfehérvár
ZIP/Postal Code
8000
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Cork
ZIP/Postal Code
T12 DV56
Country
Ireland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Dublin
ZIP/Postal Code
D09 V2N0
Country
Ireland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Dublin
ZIP/Postal Code
D24 NR0A
Country
Ireland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Galway
ZIP/Postal Code
H91 YR71
Country
Ireland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Fujieda-shi
ZIP/Postal Code
426-8677
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Itabashi-ku
ZIP/Postal Code
173-8610
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Kawachinagano-shi
ZIP/Postal Code
586-8521
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Toyonaka-shi
ZIP/Postal Code
560-8552
Country
Japan
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Kajang
ZIP/Postal Code
43000
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Kota Bahru
ZIP/Postal Code
15586
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Kuala Lumpur
ZIP/Postal Code
59100
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Sarawak Miri
ZIP/Postal Code
98000
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Seremban
ZIP/Postal Code
70300
Country
Malaysia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Arnhem
ZIP/Postal Code
6815 AD
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Breda
ZIP/Postal Code
4818 CK
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Den Bosch
ZIP/Postal Code
5223 GZ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Groningen
ZIP/Postal Code
9728 NT
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Harderwijk
ZIP/Postal Code
3844 DG
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Heerlen
ZIP/Postal Code
6419 PC
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Roermond
ZIP/Postal Code
6043 CV
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Rotterdam
ZIP/Postal Code
3045 PM
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Rotterdam
ZIP/Postal Code
3083 AN
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Zutphen
ZIP/Postal Code
7207 AE
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Hat Yai
ZIP/Postal Code
90110
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Khlong Luang
ZIP/Postal Code
12120
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Muang
ZIP/Postal Code
22000
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Muang
ZIP/Postal Code
40002
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Nakhon Ratchasima
ZIP/Postal Code
30000
Country
Thailand
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at : https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD Sharing URL
https://vivli.org/

Learn more about this trial

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

We'll reach out to this number within 24 hrs